360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Bapineuzumab

Type: Product

Name: Bapineuzumab

First reported May 16 2013 - Updated May 17 2013 - 3 reports

Baxter International Inc

Baxter International Inc. (BAX), Eli Lilly & Co. (LLY): Diagnosing Alzheimer’s First

Alzheimer’s is a debilitating neurodegenerative disorder affecting approximately 5 million Americans, yet its causes are remarkably enigmatic. Nonetheless, pharma and biotech companies continually throw money at potential blockbusters that lack innovative ... [Published InsiderMonkey.com - May 17 2013]

Entities: Alzheimer's Disease, Baxter International Inc, Eli Lilly & Company, Gammagard

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Considering Anti-Amyloid Immunotherapy

Amyloids are solid masses that form in tissues as a result of misfolded proteins. The amount of amyloid increases with age, perhaps due to a failure of mechanisms that keep the levels of damaged or misfolded proteins under control, and this is thought ... [Published Fight Aging! - May 15 2013]

Entities: Immunotherapy, Protein, Species, Alzheimer's Disease

First reported May 10 2013 - Updated May 10 2013 - 1 reports

Pfizer Inc

Alzheimer's keeps frustrating big pharma

Chances are, probably not. Years of research and tests by the pharmaceutical industry, which looks to benefit from patents for an effective Alzheimer's treatment, have so far yielded little to no positive results. And that's leading to questions about ... [Published MSN Money - May 10 2013]

Entities: Alzheimer's Disease, Pfizer Inc, Drugs, Dimebolin, Patient

First reported May 08 2013 - Updated May 08 2013 - 1 reports

Johnson & Johnson

Drugmakers contribute to Oxford initiative to prevent costly failed trials

With the news of Baxter ’s Phase III Alzheimer’s drug Gammagard missing its primary endpoints – and thus joining the list of unsuccessful Alzheimer’s trials that includes Pfizer and J&J’s bapineuzumab – drug manufacturers will be looking for ways to avoid ... [Published Terrapinn - May 08 2013]

Entities: Drugs, Johnson & Johnson, Pfizer Inc, Alzheimer's Disease

First reported Apr 29 2013 - Updated Apr 30 2013 - 1 reports

Otsuka to Build 3-Pronged Attack on Alzheimer’s With Lundbeck

April 29 (Bloomberg) -- Otsuka Holdings Co., which last month agreed to pay H. Lundbeck A/S as much as $825 million to advance an experimental Alzheimer’s treatment, plans to develop two more drugs with its Danish partner targeting different aspects of ... [Published Washington Post - Apr 29 2013]

Entities: Alzheimer's Disease, Drugs, Kristen Hallam, Taro Iwamoto, Otsuka Holdings Co Ltd

First reported Apr 28 2013 - Updated Apr 28 2013 - 2 reports

Merck & Co Inc

Pfizer and 3 Dow Healthcare Stocks Driving Headlines This Week

Pfizer ( NYSE:PFE ): Current price $30.14Levi & Korsinsky says that a class action lawsuit has begun in the United States District Court for the Southern District of New York, on behalf of investors who purchased Wyeth, now part of Pfizer stock between ... [Published Wall St. Cheat Sheet - Apr 28 2013]

Entities: Pfizer Inc, Merck & Co Inc, Drugs, Johnson & Johnson, Clinical trials

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Eli Lilly & Company

Eli Lilly slugs it out with J&J on Alzheimer's drug patent claim

With a new late-stage study being prepped for the Alzheimer's drug solanezumab, Eli Lilly found itself in a London courtroom this week defending itself against a patent claim by Johnson & Johnson, one of its chief rivals in the risky game of Alzheimer's ... [Published FierceBiotech - Apr 25 2013]

Entities: Eli Lilly & Company, Alzheimer's Disease, Patent Claim, Johnson & Johnson

First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Acumen Pharma reveals A round closing to fund Alzheimer's drug research

Driven to test another amyloid-beta mechanism in Alzheimer's, Acumen Pharmaceuticals has wrapped up the first closing of a planned $20 million Series A round from BVF Partners, NeuroVentures Fund, Praxis Technologies, Glynn Ventures and private backers. ... [Published FierceBiotech - Apr 25 2013]

Entities: Alzheimer's Disease, A ROUND, Merck & Co Inc, Drugs, Acumen Pharmaceuticals Inc

First reported Apr 22 2013 - Updated Apr 22 2013 - 2 reports

Boeing Installs Lithium Batteries and 2 More Dow Movers to Watch

The Boeing Company ( NYSE:BA ): Current price $86.79On Monday, Boeing began the installations of reinforced lithium ion batteries on five grounded 787 jets owned by the launch customer All Nippon Airways , thus commencing a process that should make the ... [Published Wall St. Cheat Sheet - Apr 22 2013]

Entities: Boeing Company, HP Converged Infrastructure, Lithium

First reported Apr 19 2013 - Updated Apr 19 2013 - 2 reports

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Investors With Losses on Their Investment in Wyeth of C

(GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who acquired Wyeth, now part of Pfizer, Inc. ("Wyeth" or "the ... [Published Interest!ALERT - Apr 19 2013]

Entities: Wyeth LLC, Bapineuzumab, Clinical trials, United States District Court for the Southern D..., Élan Corporation plc

First reported Apr 17 2013 - Updated Apr 17 2013 - 2 reports

Brower Piven Encourages Investors Who Purchased 20,000 or More Shares of Wyeth Common Stock to Inquire GlobeNewswire

(GLOBE NEWSWIRE) -- Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Wyeth ("Wyeth" or the "Company") ... [Published Yahoo! Finance - Apr 17 2013]

Entities: Wyeth LLC, Common Shares, Bapineuzumab, Professional Corporation, Clinical trials

First reported Apr 15 2013 - Updated Apr 16 2013 - 2 reports

CEO Chris Viehbacher steers Sanofi clear of drugs for Alzheimer's disease

Any company that can develop a drug even partially effective against Alzheimer's disease will strike a gold mine. One analyst estimates the opportunity to be $20 billion, but most attempts so far have been costly failures. Think Pfizer ($PFE) and Johnson ... [Published FiercePharma - Apr 15 2013]

Entities: Chris Viehbacher, Sanofi SA, Alzheimer's Disease

Quotes

Elan CEO Kelly Martin told Reuters the moves are not about Royalty's overtures, but are about adding shareholder value. "[Do] they want to sell their shares to Royalty at a discount or do they want to continue to be invested in an entity that is creating a portfolio of interesting and different assets?" Diane Alter has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned...

Flush With Cash, Elan Goes on a Buying Spree [Published Motley Fool - 19 hours ago]

The Board of Elan CorporationElan Corporation plc (NYSE : ELN) (Elan) notes today$ "s announcement regarding the revised offer by Echo Pharma Acquisition Limited ($SRoyalty Pharma⬝) to acquire Elan's shares under Rule 2.5 of the IrishIrish Takeover Rules."

Elan's Response to Royalty Pharma Announcement [Published MoneyAM - 23 hours ago]

"We've gone from a decade-long focus on neurology and pivoted to diversify away from neurodegenerative disease" Mr. Martin said in an interview...

Elan Sets Out Deal Plans [Published 4 Traders - May 20 2013]

"This is a one defendant case, involving trades in two securities, both relating to the outcome of a single event: the publicpublic announcement of the drug trial results on July 29, 2008" Assistant U S Attorney Arlo Devlin-Brown wrote in the papers filed yesterday

Martoma Faces Evidence From Trades to E-Mails, U.S. Says (1) [Published BusinessWeek - May 14 2013]

More Content

sort by: Date \| Relevance
Flush With Cash, Elan Goes on a Buying Spree [Published Motley Fool - 19 hours ago]
Vitamins That Cost Pennies a Day Seen Delaying ... [Published Washington Post - 21 hours ago]
Elan's Response to Royalty Pharma Announcement [Published MoneyAM - 23 hours ago]
Elan Sets Out Deal Plans [Published 4 Traders - May 20 2013]
Elan Announces Transactions: Decisively Transfo... [Published Yahoo! Finance - May 20 2013]
Delivery system for cytotoxic drugs by bispecif... [Published PharmCast - May 19 2013]
Baxter International Inc. (BAX), Eli Lilly & Co... [Published InsiderMonkey.com - May 17 2013]
Diagnosing Alzheimer's First [Published Motley Fool - May 17 2013]
Any Light at the End of the Tunnel for Alzheime... [Published Motley Fool Discussion Boards - May 16 2013]
Considering Anti-Amyloid Immunotherapy [Published Fight Aging! - May 15 2013]
Martoma Faces Evidence From Trades to E-Mails, ... [Published BusinessWeek - May 14 2013]
Is Alzheimer's Prevention a (Soon to Be) New Re... [Published American Society On Aging - May 14 2013]
Elan Provides Additional Commentary on Elan/The... [Published Business Wire - May 13 2013]
Alzheimer's keeps frustrating big pharma [Published MSN Money - May 10 2013]
Baxter's Gammagard fails in PhIII Alzheimer's t... [Published Pharma Times - May 08 2013]
Drugmakers contribute to Oxford initiative to p... [Published Terrapinn - May 08 2013]
Promising Alzheimer’s Treatment Fails, Drug Mak... [Published New York Times - May 07 2013]
UPDATE 2-Baxter's Alzheimer's disease drug fail... [Published Reuters - May 07 2013]
Baxter Alzheimer's Drug Fails Phase III Trial [Published Genetic Engineering News - May 07 2013]
UPDATED: Baxter adds Gammagard to growing roste... [Published FierceBiotech - May 07 2013]
Otsuka Pursuing Three-Pronged Alzheimer’s Attac... [Published Washington Post - Apr 30 2013]
Otsuka to Build 3-Pronged Attack on Alzheimer’s... [Published Washington Post - Apr 29 2013]
Pfizer and 3 Dow Healthcare Stocks Driving Head... [Published Wall St. Cheat Sheet - Apr 28 2013]
Pfizer and 3 Dow Healthcare Stocks Driving Head... [Published Wall St. Cheat Sheet - Apr 28 2013]
Eli Lilly slugs it out with J&J on Alzheimer's ... [Published FierceBiotech - Apr 25 2013]
Acumen Pharma reveals A round closing to fund A... [Published FierceBiotech - Apr 25 2013]
Eli Lilly Sues J&J for Patents Rights in Alzhei... [Published Bloomberg - Apr 25 2013]
Boeing Installs Lithium Batteries and 2 More Do... [Published Wall St. Cheat Sheet - Apr 22 2013]
Boeing Installs Lithium Batteries and 2 More Do... [Published Wall St. Cheat Sheet - Apr 22 2013]
Lilly And Sanofi CEOs Take Two Very Different R... [Published Forbes.com - Apr 22 2013]

Blogs

sort by: Date \| Relevance
Considering Anti-Amyloid Immunotherapy [Published Fight Aging! - May 15 2013] Amyloids are solid masses that form in tissues as a result of misfolded proteins. The amount of amyloid increases with age, perhaps due to a failure of mechanisms that keep the levels of damaged or misfolded proteins under control, and this is thought ...
Pfizer and 3 Dow Healthcare Stocks Driving Head... [Published Wall St. Cheat Sheet - Apr 28 2013] Pfizer ( NYSE:PFE ): Current price $30.14Levi & Korsinsky says that a class action lawsuit has begun in the United States District Court for the Southern District of New York, on behalf of investors who purchased Wyeth, now part of Pfizer stock between ...
Pfizer and 3 Dow Healthcare Stocks Driving Head... [Published Wall St. Cheat Sheet - Apr 28 2013] Pfizer ( NYSE:PFE ): Current price $30.14 Levi & Korsinsky says that a class action lawsuit has begun in the United States District Court for the Southern District of New York, on behalf of investors who purchased Wyeth, now part of Pfizer stock between ...
Boeing Installs Lithium Batteries and 2 More Do... [Published Wall St. Cheat Sheet - Apr 22 2013] The Boeing Company ( NYSE:BA ): Current price $86.79On Monday, Boeing began the installations of reinforced lithium ion batteries on five grounded 787 jets owned by the launch customer All Nippon Airways , thus commencing a process that should make the ...
Boeing Installs Lithium Batteries and 2 More Do... [Published Wall St. Cheat Sheet - Apr 22 2013] The Boeing Company ( NYSE:BA ): Current price $86.79 On Monday, Boeing began the installations of reinforced lithium ion batteries on five grounded 787 jets owned by the launch customer All Nippon Airways , thus commencing a process that should ...

Press Releases

sort by: Date \| Relevance
Elan Provides Additional Commentary on Elan/The... [Published Business Wire - May 13 2013]
Pharma IQ a mis au point l'exposé du secteur su... [Published PR Newswire - Aug 24 2012]